Skip to main content

$0.125 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
2 July 2025 at 2:05pm
Register to track EMD and receive email alerts.
Subject
EMD Ann: Notice of General Meeting/Proxy Form

EMD Ann: Change in substantial holding SW

EMD Ann: Emyria adds consultant psychiatrist to Medical Advisory

EMD Ann: FDA Position on RWE to Guide Registration

EMD Ann: Appendix 4C - Quarterly

EMD Ann: Emyria Pursuing Registration of EMD-003 in CY2021

EMD Ann: Appendix 2A and Notice Under Section 708A

EMD Ann: Emyria to Benefit from Final TGA Ruling on CBD Medicines

EMD Ann: Proposed issue of Securities - EMD

EMD Ann: Proposed issue of Securities - EMD

EMD Ann: Proposed issue of Securities - EMD

EMD Ann: Emyria to Accelerate Drug Development with $1.2m Placement

EMD Ann: Trading Halt

EMD Ann: Product Launch Update

EMD Ann: Emyria Sees Strong Interest in IBS Study

EMD Ann: Emyria Launches Drug Development Program Based on RWE

EMD Ann: Emyria Partners with Thought Leaders in Psychedelic Therapy

EMD Ann: Change of Director's Interest Notice SW

EMD Ann: Change of Director's Interest Notice * 4

EMD Ann: Appendix 3G

EMD Ann: Results of Meeting

EMD Ann: Annual General Meeting Presentation

EMD Ann: Exercise Price of Options

EMD Ann: Emyria Enters Data Deal with Zelira to Support Autism Trial

EMD Ann: Release of Unlisted Options from Escrow

EMD Ann: Emyria receives $954,000 R&D tax incentive refund

EMD Ann: Appendix 4C - Quarterly

EMD Ann: Change of Director's Interest Notice AV

EMD Ann: Webinar on Global Partnership with Sapphire Medical Clinics

EMD Ann: Emyria Enters into Partnership with Sapphire Medical Clinics

Register to track EMD and receive email alerts.

Similar Companies

EHE
JHC
MVF
ONT
PSQ
REG
RHC
VRT